Sep 20, 2021 Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy
Aug 6, 2021 Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
Aug 6, 2021 Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
Jul 22, 2021 Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 20, 2021 Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer
May 13, 2021 Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
May 10, 2021 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 7, 2021 Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
